JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $165

Benzinga Newsdesk www.benzinga.com Negative 92.5%

Neg 92.5% Neu 0% Pos 0%

JP Morgan analyst Casey Woodring maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $180 to $165.